Reduced Release of Intact and Cleaved Urokinase Receptor in Stimulated Whole-Blood Cultures from Human Immunodeficiency Virus-1-Infected Patients
- 1 April 2005
- journal article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 61 (4) , 347-356
Abstract
The blood levels of the soluble forms of the urokinase receptor (suPAR) are increased in human immunodeficiency virus (HIV)-1-infected patients. This study investigated whether the release of urokinase-type plasminogen activator receptor (uPAR) in whole-blood cultures was affected by HIV infection. The release of different uPAR forms in whole-blood cultures incubated 24 h with or without phytohemagglutinin and lipopolysaccharide was analysed in 47 HIV patients and 19 controls. suPAR was measured by enzyme-linked immunosorbent assay (ELISA) (bulk-suPAR) and three different time-resolved fluorescence immunoassays measuring three-domain suPAR [suPAR(I-III)], three- and two-domain suPAR [suPAR(I-III) + suPAR(II-III)] and one-domain suPAR [suPAR(I)]. The uPAR release was correlated to leucocyte subpopulations and plasma levels of suPAR. The stimulated net whole-blood culture release of bulk-uPAR, uPAR(I-III), uPAR(II-III) and uPAR(I) was reduced in HIV patients (all P < 0.01), whereas the spontaneous bulk-uPAR and uPAR(I-III) release was increased in HIV patients (both P < 0.05). The stimulated uPAR release in whole-blood cultures correlated well to leucocytes and circulating suPAR levels in controls, whereas the correlation was weaker to leucocytes and nonexisting to circulating suPAR levels in HIV patients. These findings demonstrate that HIV infection affects stimulated and spontaneous uPAR release in whole-blood cultures. Given that high blood levels of suPAR in HIV patients are linked to immune activation, the perturbations in uPAR release in whole-blood cultures from HIV patients may also reflect immune activation.Keywords
This publication has 40 references indexed in Scilit:
- Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase ReceptorClinical Chemistry, 2004
- Soluble Urokinase Receptor Levels in Plasma During 5 Years of Highly Active Antiretroviral Therapy in HIV-1???Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Borrelia burgdorferi and Other Bacterial Products Induce Expression and Release of the Urokinase Receptor (CD87)The Journal of Immunology, 2001
- Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivoFEBS Letters, 2000
- Upregulation of Monocyte Urokinase Plasminogen Activator Receptor during Human EndotoxemiaInfection and Immunity, 2000
- Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expressionJournal of Cellular Physiology, 1999
- Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assayInternational Journal of Cancer, 1998
- The urokinase receptorFibrinolysis and Proteolysis, 1998
- Expression of the Receptor for Urokinasetype Plasminogen Activator in Normal and Neoplastic Blood Cells and Hematopoietic TissueAmerican Journal of Clinical Pathology, 1994
- Identification and characterization of urokinase receptors in natural killer cells and T‐cell‐derived lymphokine activated killer cellsFEBS Letters, 1992